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Challenging immunodominance of inﬂuenza-
speciﬁc CD8+ T cell responses restricted by the
risk-associated HLA-A*68:01 allomorph
C.E. van de Sandt 1,2,17, E.B. Clemens1,17, E.J. Grant1,15, L.C. Rowntree1, S. Sant1, H. Halim3, J. Crowe4,
A.C. Cheng5,6, T.C. Kotsimbos7,8, M. Richards9, A. Miller10,16, S.Y.C. Tong9,11, J. Rossjohn 3,12,13,
T.H.O. Nguyen1, S. Gras3,12, W. Chen 14 & K. Kedzierska 1*
Although inﬂuenza viruses lead to severe illness in high-risk populations, host genetic factors
associated with severe disease are largely unknown. As the HLA-A*68:01 allele can be linked
to severe pandemic 2009-H1N1 disease, we investigate a potential impairment of HLA-
A*68:01-restricted CD8+ T cells to mount robust responses. We elucidate the HLA-A*68:01
+CD8+ T cell response directed toward an extended inﬂuenza-derived nucleoprotein (NP)
peptide and show that only ~35% individuals have immunodominant A68/NP145+CD8+
T cell responses. Dissecting A68/NP145+CD8+ T cells in low vs. medium/high responders
reveals that high responding donors have A68/NP145+CD8+ memory T cells with clonally
expanded TCRαβs, while low-responders display A68/NP145+CD8+ T cells with pre-
dominantly naïve phenotypes and non-expanded TCRαβs. Single-cell index sorting and
TCRαβ analyses link expansion of A68/NP145+CD8+ T cells to their memory potential. Our
study demonstrates the immunodominance potential of inﬂuenza-speciﬁc CD8+ T cells
presented by a risk HLA-A*68:01 molecule and advocates for priming CD8+ T cell com-
partments in HLA-A*68:01-expressing individuals for establishment of pre-existing protective
memory T cell pools.
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A lthough 2018 marked the 100th anniversary of theSpanish inﬂuenza pandemic, which killed >50 millionpeople1, inﬂuenza viruses remain a constant global health
threat. Indeed, a global inﬂuenza pandemic is listed as one of the
WHO Top Ten Global Health Threats in 20192. The next inﬂu-
enza pandemic outbreak is inevitable and the mechanisms leading
to differential disease outcomes are unclear. Therefore, it is
important to understand why some individuals succumb to severe
and fatal inﬂuenza disease during pandemic outbreaks and sea-
sonal epidemics1,3.
Although current antibody-based vaccines targeting variable
hemagglutinin (HA) and neuraminidase (NA) surface glycopro-
teins are the most effective way to combat seasonal infections,
they fail during an inﬂuenza pandemic caused by the emergence
of an antigenically distinct inﬂuenza virus subtype4,5. In the
absence of protective antibodies, a novel inﬂuenza A virus (IAV)
can activate and recall memory cross-strain protective cytotoxic
CD8+ T cells, speciﬁc for conserved viral peptides6–11, resulting
in rapid viral clearance and reduced disease severity12,13. This
makes cross-reactive CD8+ T cells an attractive target for novel
universal inﬂuenza vaccine strategies5. Following the 2013 H7N9
outbreak in China, we illustrated the importance of robust pre-
existing cytotoxic CD8+ T cells memory for protection against
severe inﬂuenza disease (and death) caused by novel IAVs13,14.
Our recent study introduces a new paradigm, whereby human
CD8+ T cells confer unprecedented cross-reactivity across all
inﬂuenza A, B, and C viruses, having key implications for the
design of universal vaccines that do not require annual refor-
mulation11. Vaccines eliciting cross-reactive CD8+ T cells would
reduce annual rates of inﬂuenza A and B virus-induced mor-
bidity/mortality, protect children from inﬂuenza C virus, and
augment CD8+ T cells in people with previous inﬂuenza
exposures5,11.
CD8+ T cells recognize virus-derived peptides in the context of
human leukocyte antigen (HLA) class I molecules via their T cell
receptors (TCRs) to speciﬁcally eliminate virus-infected cells15.
HLA-A*01:01, HLA-A*02:01, HLA-A*03:01, HLA-B*08:01, HLA-
B*18:01, HLA-B*27:05, HLA-B*37:01, and HLA-B*57:019–11 are
associated with universal protective CD8+ T cell mediated
immunity, as they present inﬂuenza peptides that were highly
conserved over the last century. Conversely, two independent
studies associated the HLA-A*68:01 allele, which is expressed at
5.2–25% allele frequency, with severe inﬂuenza disease during the
2009 inﬂuenza pandemic16,17. To understand CD8+ T cell
responses in the context of the high risk HLA-A*68:01 molecule,
we have recently identiﬁed a novel extended 12 amino acid
inﬂuenza-derived peptide from the virus nucleoprotein (NP145–156;
DATYQRTRALVR) with the capacity to bind to HLA-A*68:0118.
HLA class I molecules predominantly bind short viral peptides
(8–10 amino acids; aa)19, although extended peptides (>10 aa)
can be presented to CD8+ T cells in the context of HLA
class I19–21. Similar to canonical length peptides (8–10 aa), longer
peptides (≥11 aa) have similar anchor residues at the second (P2)
and last position (PΩ). As a result, the central region of these
extended peptides is forced to bulge from the HLA class I
antigen-binding cleft19,20, although >11 aa peptides that extent
from the N- or C-terminus have been described22,23. The bulging
conformation of the extended HLA class I-restricted peptides
may prove especially challenging for TCR recognition24,25. Based
on a limited amount of studies on long peptide-speciﬁc TCR
repertoires, it appears that long peptide-HLA class I complexes
drive a biased TCR gene usage, suggesting that bulging peptide-
HLA class I complexes can only be recognized by few TCRs,
which may affect CD8+ T cell recruitment26–31. Conversely, the
bulging part of the peptide can also display high mobility, pro-
viding multiple TCR binding sites, thus selecting a diverse TCR
repertoire32,33. Indeed, a diverse TCR repertoire has been
demonstrated for two long peptides (HLA-B*07:02/NY-ESO-1
(13 aa) and HLA-B*57:03-KF11 (11 aa))20,30,34.
In the present study, we elucidate the contribution of CD8+
T cell responses directed toward this novel extended HLA-
A*68:01-NP145-156 (hereafter A68/NP145) epitope to the overall
inﬂuenza-speciﬁc immunity. Understanding the role of CD8+
T cells presenting inﬂuenza viral peptides in the context of risk
HLA-I molecules such as HLA-A*68:01 is of key importance to
rationally design universal T cell-targeted inﬂuenza virus vac-
cines. Here, we provide an in-depth analysis of inﬂuenza virus-
speciﬁc CD8+ T cells directed against the extended 12 aa NP145
peptide restricted by the risk HLA-A*68:01 molecule. Our data
show an immunodominance potential of inﬂuenza-speciﬁc CD8+
T cells in the context of a risk HLA-A*68:01 molecule in 35%
donors and advocates for priming CD8+ T cell compartments in
HLA-A*68:01-expressing individuals for establishment of pre-
existing protective memory CD8+ T cell pools against future
unpredicted inﬂuenza strains.
Results
Structural ﬂexibility of NP145 peptide bound to HLA-A*68:01.
An inﬂuenza-derived 12 aa peptide NP145 (DATYQRTRALVR),
presented by an inﬂuenza risk HLA-I allomorph HLA-A*68:0118,
is one of a relatively few immunogenic (derived from pathogens)
human CD8+ T cell peptides over 11 aa reported to date19. To
understand whether presentation of this extended NP145 peptide
(hereafter NP145) within HLA-A*68:01 was associated with any
structural constraints, which potentially could affect TCR recog-
nition of the A68/NP145 epitope, we solved the structure of the
HLA-A*68:01-NP145 complex at a resolution of 1.90 Å (Supple-
mentary Table 1). The structure showed that the anchor residue
Ala at P2 was bound within the HLA-A*68:01 peptide-binding
groove, despite being smaller than the usual P2 anchor residues
for HLA-A*68:01 (Val or Thr) (Fig. 1a). The C-terminal part of
the NP145 peptide possessed a canonical HLA-A*68:01 anchor
residue Arg at P12, which formed a network of salt bridges with
Asp77, Asp74, and Asp114 within the HLA-A*68:01 molecule
(Fig. 1b). In contrast, the central section (residues P4–P9) of the
NP145 peptide presented weak/no electron density associated with
a high degree of peptide mobility, despite the well-deﬁned elec-
tron density of the N- and C-terminal ends of the NP145 peptide
(Fig. 1c, d). The ﬂexible nature of the NP145 peptide might
potentially present a challenge for TCR engagement, thereby
limiting the recruitment of A68/NP145-speciﬁc CD8+ T cells
during inﬂuenza virus infection.
Conservation of the NP145 peptide across IAVs. As variations
within the viral peptide can affect peptide-HLA class I binding
and presentation15,35–39, as well as TCR recognition9,15,40,41, we
next assessed the conservation level of the NP145 peptide within
the inﬂuenza viruses. We examined 24,408 nucleoprotein (NP)
sequences derived from human A/H1N1 (1918–1957 n= 77,
1977–2008 n= 1132, 2009–2018 n= 9291), A/H2N2 (1957–1968
n= 119) and A/H3N2 (1986–2018 n= 13,497) viruses as well as
avian A/H5N1 (1997–2014 n= 194), and A/H7N9 (2013–2017
n= 98) viruses (human isolates) (NCBI; http:/www.ncbi.nlm.nih.
gov/genomes/FLU database, accessed on July 31, 2018). Based on
our sequence alignments, we found that while amino acids at
positions 145, 147–156 within the viral NP145 peptide were highly
conserved (Supplementary Table 2), variability was observed at
position 146 (P2 of the peptide), with inﬂuenza viruses expressing
either an alanine (A) (21,740/24,408 viruses, 89.1%) or threonine
(T) (2661/24,408 viruses, 10.9%), and to a lesser extent a valine
(V) (7/24,408 viruses; <0.01% (Supplementary Table 2; Fig. 2a).
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Chronological analyses of the residues at position 146 showed
that these variations were not randomly distributed, but instead
became ﬁxed with time. While the earliest known inﬂuenza virus
isolates from 1918 had an alanine at position 146, this was
replaced by an A146T substitution in 1935. The 146T variant of
the NP145–146 peptide was passed onto the A/H2N2 and subse-
quently the A/H3N2 viruses by two reassortment events1. The
146T variant of the NP145 peptide continued to circulate until
2001 when the T146A substitution was rapidly ﬁxed and con-
tinues to circulate until now. The 1957 A/H1N1 virus (146T) was
reintroduced in the human population in 1977 and continued to
circulate up to 2009, when it was replaced by a multiple reas-
sorted A/H1N1 virus that contained the original NP gene seg-
ment from 1918 (146A)1 (Fig. 2a). With the exception of the A/
Shandong/1/2009 strain, all human viral isolates of the avian A/
H5N1 and A/H7N9 viruses express an alanine at position 146
(Fig. 2a, Supplementary Table 2).
Despite virus antigenic variations, inﬂuenza-speciﬁc CD8+
T cells can provide broad cross-reactivity and recognize an array
of peptide variants6,8,10,15,41–44. Thus, we analysed the cross-
reactive potential of A68/NP145+CD8+ T cells toward the two
main NP145 variants, DATYQRTRALVR and DTTYQRTRALVR,
as well as the less prevalent DVTYQRTRALVR variant. Given
that the 146A and 146T variants of the NP145- peptide have
predominantly circulated in the last two decades, both NP145
peptide variants were able to expand A68/NP145+CD8+ T cells
(Fig. 2b, c, Supplementary Fig. 1a). The FACS plots are
representatives of 146A peptide-stimulated and expanded A68/
NP145-speciﬁc CD8+ T cells at day 10. DMSO was used as a
negative control for the second 6-h restimulation in an IFN-γ ICS
assay of these expanded cells, thus the large population of
tetramer-positive cells resulted from the initial expansion after the
ﬁrst stimulation (Fig. 2b). However, negligible IFN-γ production
was detected in the DMSO control (Fig. 2b). Re-stimulating the
expanded A68/NP145+CD8+ T cells with three variants of the
NP145 peptide (146A, 146T, and 146V) revealed a substantial level
of cross-reactivity toward all three peptides (Fig. 2c, n= 3
donors). The high level of cross-reactivity between the 146A,
146T, and 146V peptide variants suggests that ﬁxation of these
mutations at position 146 did not result in viral escape from pre-
existing A68/NP145+CD8+ T cell responses and would therefore
not be a determining factor in HLA−A*68:01-associated
morbidity when a new variant is introduced.
Since the NP145-146A variant of the NP145 peptide circulated in
the past two decades, and is cross-reactive with the other variants,
we selected this immunogenic DATYQRTRALVR peptide to
further dissect the quantitative, qualitative, and clonal character-
istics of A68/NP145-speciﬁc CD8+ T cell responses in HLA-
A*68:01-expressing individuals.
A68/NP145-+CD8+ T cell responses vary across the donors. To
probe the magnitude of established A68/NP145+CD8+ T cell
populations, we assessed A68/NP145-speciﬁc CD8+ T cells
directly ex vivo using a tetramer-associated magnetic enrichment
(TAME)43,45 in 17 healthy HLA-A*68:01-expressing individuals
(Fig. 3a, b, Supplementary Fig. 1b, Table 1). Frequencies of A68/
NP145+CD8+ T cells, calculated relative to total CD8+ T cell
numbers in an unenriched fraction45,46, were compared with
frequencies of inﬂuenza virus-speciﬁc CD8+ T cell responses
directed against other well-known prominent universal HLAs
(Table 1, in bold)9,10 using single- or dual-tetramer enrichments.
The frequencies of tetramer-enriched A68/NP145+CD8+ T cells
revealed three types of A68/NP145-speciﬁc CD8+ T cell respon-
ders (Fig. 3b). Out of 17 individuals, 11 were classiﬁed as low
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Fig. 1 Structure of the HLA-A*68:01-NP145 complex. Structure of the HLA-A*68:01 (white cartoon) bound to the NP145 peptide (orange stick). a A zoomed
view of the P2-Ala anchor residue interaction with the HLA-A*68:01 molecule, the blue dashed lines represent hydrophobic interactions. b The P12-Arg salt
bridge network (red dashed lines) with the HLA-A*68:01 amino acids. c, d The electron density maps after reﬁnement (c 2Fo-Fc map colored in purple and
contoured at 1 σ) or before building the peptide in d (Fo-Fc or omit map colored in green and contoured at 3 σ). The orange dashed line on c, d represent
the missing amino acid from the NP145 peptide (P4–P8) in the crystal structure.
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Fig. 2 High conservation of the NP145-156 peptide across seasonal IAV viruses. a Frequency of amino acid variation at position 146 of the NP145–156 peptide.
Pie charts represent frequency of alanine (A; white), threonine (T; gray) and valine (B, black) at position 146. Total number of analyzed sequences are
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(1986–2018 n= 13,497), avian A/H5N1 (1997–2014 n= 194) and A/H7N9 (2013–2017 n= 98). b Representative FACS panels of A68/NP145-speciﬁc
CD8+ T cells expanded by 146A peptide stimulation on day 0, followed by restimulation at day 10 with cognate or variant NP145 peptides. Day 10
restimulation with PMA/Ionomycin was included as a positive control and DMSO as a negative control. c Percentage of maximum IFNγ+CD3+CD4−
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responders with <12 A68/NP145+CD8+ T cells/106 CD8+ T cells.
Within those, seven donors had a total of <10 counted A68/
NP145+CD8+ T cells within the whole enriched fraction, which
was sufﬁcient for analysis of frequencies but not phenotypes
(Supplementary Fig. 2). The remaining six donors (35%)
displayed substantial pools of A68/NP145+CD8+ T cells,
with four donors being medium responders (>12 A68/
NP145+CD8+ T cells/106 CD8+ T cells) and two donors being
high responders (>100 A68/NP145+CD8+ T cells/106 CD8+
T cells) (Fig. 3b).
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Strikingly, within the low-responders, A68/NP145+CD8+ T cell
pools were subdominant as compared with the frequency of other
dominant universal inﬂuenza-speciﬁc CD8+ T cell populations
within the same individuals (p= 0.00056; Fig. 3b, c). In contrast,
the frequencies of A68/NP145+CD8+ T cells within medium and
high responders were comparable to the frequencies of CD8+
T cells directed at universal inﬂuenza epitopes (p= 0.153; Fig. 2b,
d), indicating the immunodominance potential of A68/
NP145+CD8+ T cells in at least some donors. These results
clearly demonstrate that the establishment of substantial A68/
NP145+ CD8+ T cell populations is far from being uniform across
the donors (p= 0.001, Fig. 3e). Although there was a trend for a
lower overall CD8+ T cell frequency directed at the universal
inﬂuenza epitopes in the low responders, as compared with the
medium and high responders, this was not signiﬁcant (p= 0.058,
Fig. 3f). In addition, no correlation was found between the
frequency of A68/NP145+CD8+ T cells and the frequency of
CD8+ T cells directed against the universal epitopes (n= 13,
Rs= 0.3518, p= 0.1397, Supplementary Fig. 3). Including addi-
tional donors may further strengthen the trend for an overall
lower inﬂuenza virus-speciﬁc CD8+ T cell response in HLA-
A*68:01 positive individuals, however, could unfortunately not be
conﬁrmed due to the low frequency of HLA-A*68:01 donors in
our cohorts.
Distinct A68/NP145CD8+ T cell phenotypes across responders.
To understand whether low detection of A68/NP145+CD8+ T cell
populations found in 65% of our donors resulted from the
establishment of differential naïve/memory subsets within the
A68/NP145+ CD8+ T cells, we compared directly ex vivo the phe-
notypes of A68/NP145+CD8+ T cells both (i) across HLA-A*68:01-
expressing donors, and (ii) with phenotypes of CD8+ T cells
directed at universal inﬂuenza epitopes (Fig. 4). We used three
surface markers, CD27, CD45RA, and CD95 to delineate naïve-like
(Tnaïve, CD27+CD45RA+CD95−), effector/effector memory (Teff,
CD27−CD45RA−), terminally differentiated effector (Temra,
CD27−CD45RA+), central memory (Tcm, CD27+CD45RA−) and
stem cell memory (Tscm, CD27+CD45RA+CD95+) CD8+ T cell
subsets in low, medium, and high responding donors (Fig. 4a, b,
Supplementary Fig. 1b).
In three out of four low-responding donors, a markedly higher
proportion of the A68/NP145+CD8+ T cells displayed a naïve-like
phenotype (mean 33.77% ± 23.83; n= 4 donors), when compared
with A68/NP145+CD8+ T cells in medium/high responders
(mean 1.52% ± 2.17; n= 6 donors; p= 0.002) (Fig. 4c). In
contrast, the proportion of total memory A68/NP145+CD8+
T cells (Tcm, Temra, Teff, Tscm) (Ttotal memory) in medium/high
responders (mean 98.59% ± 1.7; n= 6 donors) was signiﬁcantly
higher compared with low responders (66.23% ± , 23.84, n= 4
donors; p= 0.002) (Fig. 4c), demonstrating a switch from naïve-
like to memory phenotypes in A68/NP145+CD8+ T cells within
medium/high responding donors.
Phenotypic analysis of the universal inﬂuenza-speciﬁc CD8+
T cell populations revealed no signiﬁcant differences within the
naïve-like (p= 0.062) or memory (p= 0.062) phenotypes when
low and medium/high responders were compared (Fig. 4d),
Fig. 3 A68/NP145-speciﬁc CD8+ T cell responses vary greatly across the donors. a Representative FACS proﬁles of A68/NP145-tetramer staining of CD8+
T cells. b Frequency of A68/NP145+ CD8+ T cells (red circles) and universal inﬂuenza virus-speciﬁc CD8+ T cells (colored squares). <12 tetramer-speciﬁc
CD8+ T cells/106 CD8+ T cells are considered low responses (n= 11), >12 tetramer-speciﬁc CD8+ T cells/106 CD8+ T cells medium responses (n= 4)
and >100 tetramer-speciﬁc CD8+ T cells/106 CD8+ T cells high responses (n= 2). Tetramer+CD8+ T cells detected at <10 cells counted within the
tetramer-positive gate are indicated in open symbols (Supplementary Fig. 2). Frequency comparison between A68/NP145- vs. universal inﬂuenza virus-
speciﬁc CD8+ T cells in low responders (c) and medium/high responders (d). e Frequency comparison of A68/NP145+CD8+ T cells between low and
medium/high responders. f Frequency comparison of universal epitope-speciﬁc CD8+ T cells between low and medium/high responders. c–f Bar indicates
mean response of the donors. Exact p values are indicated above the graphs. Low responding donors (circles), high responding donors (squares), <10 cells
counted (open symbols). Statistical analysis was performed using a Mann–Withney test. Exact p value are indicated above the graphs.
Table 1 Demographics and HLA typing of the donors used in this study.
Donor Age Sex Speciﬁcations HLA-A haplotypes HLA-B haplotypes Year of recruitment A68-NP145
Responder
D17 NR NR Healthy donor 01:01, 68:01 08:01, 15:01 NR Low
D8 30 NR Healthy adult 02:01, 68:01 07:02, 40:01 2014 Low
D11 21 NR Adenovirus infected 03:01, 68:01 40:01, 56:01 2010 Low
D1 22/25 M Healthy adult 33:03, 68:01 35:01, 58:01 a2015,b2018 Low
D9 49 NR Healthy adult 24:02, 68:01 15:18, 40:01 2013 Low
D10 29 NR Healthy adult 02:01, 68:01 40:02, 44:02 2014 Low
D2 48/51 M Healthy adult 01:01, 68:01 08:01, 40:01 a2015,b2018 Low
D4 31 F Healthy adult 03:01, 68:01 27:05, 40:01 2018 Low
D3 42/46 F Healthy adult 01:01, 68:01 37:01, 35:01 a2015,b2018 Low
D14 NR NR Healthy donor 11:01, 68:01 14:02, 35:01 2017 Low
D12 90 M Viral pneumonia Inﬂuenza
virus negative
30:02, 68:01 18:01, 35:03 2014 Low
D5 52 M Healthy adult 03:01, 68:01 07:02, 35:03 2014 Medium
D7 74 F Healthy elderly 01:01, 68:01 08:01, 44:02 2013 Medium
D6 29 M Healthy adult 33:01, 68:01 07:05, 14:02 2016 Medium
D16 NR NR Healthy donor 32:01, 68:01 14:01, 44:02 NR Medium
D13 30 NR Inﬂuenza A virus infection 02:06, 68:01 13:01, 15:18 2010 High
D15 NR NR Healthy donor 01:01, 68:01 08:01,18:01 2017 High
D18 27 M Healthy adult 01:01, 68:01 08:01 2018 NT
HLA bold indicates HLA used for TAME
NR not reported, NT not tested
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consistent with their similar response magnitudes. Detection of
memory phenotypes within all the universal CD8+ T cell sets also
veriﬁes that our A68+ donors had previous inﬂuenza encounters
and thus their A68/NP145+ CD8+ T cells were exposed to the
antigenic stimulation during previous inﬂuenza virus infection
across all the low, medium, and high responding donors.
Diverse TCRαβ repertoires within A68/NP145+CD8+ T cell
pools. To understand differential A68/NP145+ CD8+ T cell
responses across HLA-A*68:01 donors, we dissected the clonal
diversity and composition within A68/NP145+ CD8+ T cells
found in low- and medium/high-responders. We used a combi-
nation of single-cell index sorting and multiplex RT-PCR43,47 to
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amplify both TCRα and TCRβ chains within a single cell,
enabling analysis of the paired A68/NP145+CD8+ TCRαβ reper-
toire in three low-responders and ﬁve medium/high-responders
(Fig. 5, Table 2, Supplementary Table 3).
In contrast to the narrowed/skewed TCR repertoires directed at
the majority of previously reported long peptide/HLA com-
plexes26–31, the A68/NP145+CD8+ TCRαβ repertoires utilized a
broad array of TRBV (T receptor β variable) and TRAV (T
receptor α variable) gene segments in low-responders and
medium/high responders (Fig. 5a, Table 2, Supplementary
Table 3). The most common gene segments were TRBV20-1
and TRAV4 observed in six out of eight donors (Fig. 5b, c).
Interestingly, donor 7 (medium responder) and 13 (high
responder) expressed a highly restricted private TRAV and
TRBV combinations, namely TRBV6-6/TRAV4 and TRBV9/
TRAV19, respectively (Fig. 5b, c).
Further dissection of the CDR3αβ clonotypic signatures
revealed a lack of common motifs within the individual donors
(Table 2, Supplementary Table 3) and absence of a shared
CDR3αβ signature (public clonotypes) across HLA-A*68:01-
expressing donors. Both low and medium/high responders
displayed large variation in the length of the CDR3α loop
ranging from 4 to 15 aa and 3 to 12 aa, respectively (Fig. 5d).
Similarly, the length of the CDR3β loop was variable, ranging
from 7 to 12 aa in low-responders and 7 to 14 aa in medium/high
responders (Fig. 5d).
Overall, the A68/NP145+CD8+ TCRαβ repertoire was strik-
ingly diverse, with no common features shared between donors.
Thus, the A68/NP145+CD8+ T cell response does not seem to be
limited by the availability of particular TCRαβs that can recognize
the long and ﬂexible 12 aa NP145 peptide in the context of HLA-
A*68:01.
Expanded A68/NP145+TCRαβ clones in medium/high respon-
ders. Despite A68/NP145+CD8+ TCRαβ repertoire diversity in all
the low and medium/high responders, it became evident that the
A68/NP145+CD8+ TCRαβ repertoires within medium/high
responders contained a high proportion (n= 5, mean 71%, range
50–95%) of expanded TCRαβ clonotypes as compared with low
responders (n= 3, mean 2.5%, range 0–10%) (p= 0.016) (Fig. 6,
Table 2). Such high proportion of the expanded TCRαβ clono-
types within medium/high responders provides clear evidence of
a correlation between large clonal expansions and immunodo-
minance observed in medium and high A68/NP145+CD8+ T cell
responders. This further suggests that minimal clonal expansions
underlie poor pre-existing memory A68/NP145+CD8+ T cell
pools in low- and non-responders. Thus, subsequent boosting of
A68/NP145+CD8+ T cells in low responders might be one of the
ways to ensure HLA-A*68:01-expressing individuals have sub-
stantial numbers of memory A68/NP145+CD8+ T cells and
therefore at least some level of protection against unpredicted
newly-emerged inﬂuenza viruses.
Memory phenotypes associated with high frequency TCRαβs.
As our experiments used single-cell index sorting, we were in a
position to directly link the individual A68/NP145+CD8+ TCRαβ
clonotypes to the exact phenotype of each analysed TCRαβ. We
were interested to link the A68/NP145+CD8+ TCRαβ repertoires
with their respective HLA-A*68:01-NP145 tetramer avidity, as
previous reports suggested that HLA-A*68:01-speciﬁc TCRs
require high afﬁnity binding to the peptide-HLA complex
(pHLA)48 to overcome reduced afﬁnity for the CD8 binding site
due to a polymorphism at position 245 (A245V) within HLA-
A*68:0149. Before the single-cell index sort technique was avail-
able, the high and low avidity populations of A68/NP145+CD8+
T cells within donor 16 were directly single-cell sorted into two
individual plates, which revealed two distinct TCR repertoires
between the high- and low-avidity populations (Supplementary
Fig. 4). With the use of index sorting, we were able to further
discriminate between high and low avidity A68/NP145+CD8+
T cells based on their actual tetramer mean ﬂuorescence intensity
(MFI) (Fig. 7).
Of all index-sorted donors (n= 5; 1b, 2b, 3b, 6, and 7), A68/
NP145+CD8+ T cell responses within donors 2b, 6, and 7 (n= 3)
were sufﬁcient enough to discriminate between high- and low-
avidity populations and therefore to establish any direct links
between TCRαβ repertoires and their respective MFI (Fig. 7).
When focusing our analysis on the two major gene segments
observed in six out of eight donors (TRBV20-1 and TRAV4)
(Table 2, Supplementary Table 3), we found that TRBV20-1 was
more prevalent in the low avidity populations (59% of the
TRBV20-1 clonotypes across all four donors), whereas the
TRAV4 was more common in the high avidity populations
(54% of the TRAV4 clonotypes across all four donors) (Fig. 7,
Supplementary Fig. 4). Clonotype TRBV30 was only observed in
donor 6 and was more prevalent in the high avidity population
(88% of the TRBV30 clonotypes) (Fig. 7). Interestingly, in donor
7 the majority of the TCRαβ repertoire comprises of one
expanded TCRαβ clonotype TRBV6-6-CASSSPSGVYNEQ and
TRAV4−CLVGDLINSGGYNKLIF, and a number of smaller
clonotypes (Fig. 7). The dominant clonotype was found across
higher and lower MFIs. This indicates that MFI of tetramer
binding might be not only affected by TCRαβ chains but also
most probably TCR levels, TCR dynamics, TCR spatial arrange-
ments, and/or other intrinsic factors.
Subsequently, we dissected the A68/NP145+CD8+ TCRαβ
repertoires of all index-sorted donors (n= 5; 1b, 2b, 3b, 6, and
7) according to their matched phenotypes (Fig. 8). Here, we
focused on the commonly observed clonotypes TRBV20-1 and
TRAV4 (shared between donors 1b, 2b, 3b, 5, 6, 7, and 16) and
the donor-speciﬁc clonotypes TRBV30 (donor 6) and TRBV6-6
(donor 7), which were detected at relatively high frequencies in
those donors. We found that the expanded TCRαβs within
common gene segments (TRBV20-1 and TRAV4) and the high
frequency individual clonotypes (TRBV30 and TRBV6-6) were
highly prevalent in the memory CD8+ T cell populations (Fig. 8).
Fig. 4 Phenotypes of A68/NP145-speciﬁc and universal inﬂuenza-speciﬁc CD8+ T cells. a Phenotypes of A68/NP145- and universal inﬂuenza virus-speciﬁc
CD8+ T cells of low (<12 A68/NP145-speciﬁc CD8+ T cells/106 CD8+ T cells) (n= 4), medium (>12) (n= 4), and high (>100) responders (n= 2).
b Representative FACS panels indicate the gating strategy used to characterize A68/NP145-speciﬁc CD8+ T cell response. Representatives for A68/NP145-
tetramer staining (ﬁrst panel), CD27, CD45RA staining to identify Teff (CD27−CD45RA−), Temra (CD27−CD45RA+), and Tcm (CD27+CD45RA−) cells
(second panel), followed by CD95, CD8 staining to identify Tnaïve-like (CD27+CD45RA+CD95−) and Tscm (CD27+CD45RA+CD95+) cells (third panel).
Gray dots are total CD8+ T cells in unenriched sample, red dots are A68/NP145+CD8+ T cells in enriched sample. c Frequency comparison of Tnaïve and
Ttotal memory (Tcm+ Tem+ Temra+ Tscm) A68/NP145+CD8+ T cells in low vs. medium/high responders. We included two measurements for donor 1, 2, and
3: open symbols were used for samples collected in 2015, closed symbols for samples collected in 2018 (see also Table 1). d Frequency comparison of
Tnaïve-like and Ttotal memory universal-speciﬁc CD8+ T cells in low vs. medium/high responders. c–d Bar indicates mean response of the donors. Statistical
analysis was performed using a Mann–Withney test. Exact p value are indicated above the graphs.
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These results conﬁrm that the large TCRαβ clonal expansions
observed within the medium and high HLA-A*68:01-responding
donors were predominantly of the memory phenotype (Figs. 6
and 8).
Overall, our results indicate that even though the A68/
NP145+CD8+ TCRαβ repertoire is highly diverse, with preferred
TCRαβ gene usage in certain individuals, including TRBV20-1,
TRAV4, TRBV30, and TRBV6-6, largely-expanded clonotypes
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displaying a memory phenotype underlie greater A68/
NP145+CD8+ T cell response magnitude in medium to high
responders.
Discussion
In this study, we dissected the immune response against the 12 aa
NP145 peptide presented by an inﬂuenza risk-associated HLA-
A*68:01 molecule. We found that the NP145 viral peptide was
highly conserved across inﬂuenza strains, except for position 146
(P2 anchor residue position of the peptide), although this did not
result in viral escape from the A68/NP145-speciﬁc CD8+ T cell
response. The HLA-A*68:01-NP145 crystal structure revealed that
NP145 peptide is highly mobile in the cleft of the HLA-A*68:01
molecule. The low frequencies of A68/NP145+CD8+ T cells in
65% HLA-A*68:01 donors, combined with their large naïve-like
populations and non-expanded TCRαβ clonotypes, indicate that
A68/NP145+CD8+ T cells might be difﬁcult to recruit during
inﬂuenza virus infections. Conversely, largely-expanded TCRαβ
clonotypes were commonly observed in memory CD8+ Tcm
populations in medium/high responders, suggesting that it might
take several inﬂuenza exposures, thus repeated A68/NP145+CD8+
T cell boosting, to establish pre-existing immunodominant A68/
NP145+CD8+ T cell memory pools.
Donors used to study the cross-reactivity of the A68/NP145-
speciﬁc CD8+ T cell response were likely to have been exposed to
viruses expressing both the 146A and 146T variant of the NP145
peptide. Donor 6 was born in 1987, donor 18 was born in 1991.
Although the exact date of birth for donor 15 is unknown, the
donor was recruited in 2017 and would have been 18 years or
older at time of recruitment, hence born before 1999. It was
demonstrated that by the age of 3, 80% of the children would
have experienced at least one IAV infection, increasing to 100%
by the age of 750. Thus, all three donors would have been infected
with an IAV expressing the 146T variant of the peptide, which
was expressed in A/H3N2 and A/H1N1 strains circulating prior
to 2001. Even though inﬂuenza virus infection is less frequently
observed in adults than in children, adults still encounter two
inﬂuenza virus infections per decade51. It is therefore reasonable
to assume that all three donors would have had at least one
additional inﬂuenza virus infections after 2001 with either the A/
H3N2 virus strain and/or the A/H1N1pdm09 strain, both
expressing the 146A variant of the peptide. The chance that these
donors would have encountered the 146V variant of the peptide
via natural infection is highly unlikely, as this variant was only
observed in seven out of the 24408 human IAV isolates recorded
between 1918 and 2018.
Even though rapid ﬁxation of amino acids substitutions inside
CD8+ T cell epitopes, especially at anchor or TCRαβ binding
residues, are often associated with immune escape15,52, this was
not the case for the rapid ﬁxation of A146T and T146A sub-
stitutions in NP proteins of human inﬂuenza viruses. Both ala-
nine and threonine have been shown to bind in the HLA-A*68:01
binding cleft in a similar fashion. Furthermore, when we
expanded A68/NP145+CD8+ T cells from three independent
donors using the 146A or 146T variants of the NP145 peptide,
both variants expanded A68/NP145+CD8+ T cell populations and
following restimulation responded to all three variants of the
NP145 peptide (146A, 146T, and 146V, respectively), suggesting
high cross-reactivity between NP145 variants. However, according
to the IEDB database (www.iedb.org), the NP145–156 peptide
overlaps with at least four other peptides, namely NP146–154
(HLA-A*02:03, 68:02, HLA-B*14:02, 02:02, and HLA-C*06:02),
NP140–148 (HLA-A*01:01,26:01, 30:02, 80:01, HLA-B*15:01, 15:17,
35:01, 57:01, 58:01), NP140–150 (HLA-B*15:01) and NP139–156
(HLA-B*15:01). It is thus possible that the variation observed at
position NP146 is driven by the virus’ ability to escape from CD8+
T cells responses directed against one or more of these over-
lapping peptides instead. We solved the structure of the HLA-
A*68:01-NP145 with an Alanine at position 146 (P2-Ala) as this
variant was present in both A/H3N2 and A/H1N1 inﬂuenza
viruses that circulated in the last decade. We observed that the
P2-Ala is well-accommodated within the antigen-binding cleft of
HLA-A*68:01, and that the long peptide is highly mobile as
previously observed for other HLA-A*68:01-restricted peptides53.
This is in accordance with a previously solved binary structure of
HLA-A*68:01 and a 9 aa NP91–99 peptide showing that the HLA-
A*68:01-bound peptide was highly ﬂexible, thus allowing the
binding of overlapping peptides of different lengths but of con-
served residues located at P2 and PΩ53. In addition, HLA-
A*68:01 can also present peptides of canonical lengths (9–10
mer), such as the 9 aa RT313 peptide from HIV53, or a 10 aa self-
peptide with a C-terminal extension that bulges out of the cleft54,
both adopting a rigid conformation in the cleft of the HLA-
A*68:01 molecule.
Approximately 30 structures of unique MHC class I-long
peptide (≥11 aa) complexes have been structurally solved, where
2/3 displayed a rigid conformation19. TCR repertoires directed at
MHC class I-restricted long peptides, were observed to have a
highly biased TCR gene usage26–31. These observations might
suggest that TCRs have a limited capacity to engage with such
long peptide-HLA-I complexes, which may limit the recruitment
of peptide-speciﬁc CD8+ T cells during infection. This was also
observed in our donors where low frequencies of A68/
NP145+CD8+ T cells were observed in 65% HLA-A*68:01 donors
tested. A substantial proportion of the A68/NP145+CD8+ T cells
in three out of four low-responding donors displayed a naïve-like
phenotype and single (non-expanded) TCRαβ signatures. Inter-
estingly, the TCRαβ repertoire was highly diverse in six out of
eight HLA-A*68:01 donors, including all three low responding
donors. Only two other long peptides, the tumor antigen HLA-
B*07:02/NY-ESO-1 (13 aa) and HIV-p24 HLA-B*57:03/KF11 (11
aa), have been described to display a more diverse TCRαβ
repertoire20,30,34. In alignment with a study from Chan et al., we
observed variability in CDR3 length without a consensus
sequence motif20. One possible explanation is that ﬂexible long
peptides could result in multiple and potentially suboptimal
TCRαβ binding sites, leading to a more diverse TCRαβ
Fig. 5 High clonal diversity in the A68/NP145-speciﬁc TCR repertoire. a Gene segment usage and pairing landscape are shown for low (n= 3) and medium/
high (n= 5) responders. Each clonotype is assigned the same vertical length irrespective of clonotype size. Each vertical stack reﬂects V and J gene
segment usage and pairing is shown by curved connecting lines. Genes are colored by frequency of distribution. Enrichment or depletion of gene usage is
indicated by up or down arrows respectively where one arrowhead correlates to a twofold increase or decrease. b Pie charts of TRAV and TRBV gene usage
in individual donors. Total number of analyzed gene sequences are indicated within the pie charts. c Circos plots showing the distribution of TRA-TRB
paired clonotypes across donors. Each segment deﬁnes an individual clonotype and width of the segment correlates to the frequency of the clonotype.
Private clonotypes are in gray. The commonly observed clonotypes shared between different donors are shown in red (TRBV20-1) and orange (TRAV4).
d Distribution of CDR3α and CDRβ amino acid lengths in low and medium/high responding donors. An asterisk indicates that TCR clonotypes were
established on in vitro expanded T cell lines.
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repertoire20,32,33. However, the low frequency of A68/
NP145+CD8+ T cells in combination with a high variety of
TCRαβ clonotypes and less frequent TCRαβ gene segments
expressing a naïve-like phenotype, indicates that the high ﬂex-
ibility of this epitope might possibly prevent the effective
recruitment of CD8+ T cells during inﬂuenza virus infections,
thus might need to be primed by rationally-designed T cell
vaccines.
It is unlikely that the ineffective recruitment of A68/
NP145+CD8+ T cells is the result of the reduced CD8 binding
afﬁnity of the HLA-A*68:01 molecule49. Previous studies have
shown that the CD8 co-receptor maintained the majority of its
biological activity, even at extremely low binding afﬁnities55.
Furthermore, the reduced CD8 binding afﬁnity did not affect the
functional activity of HLA-A*68:01-NP89–101 and HIVTat-speciﬁc
CD8+ T cells48,55. In addition, it was shown that HLA-A*68:01-
HIVTat-speciﬁc TCR binding was within the normal TCR-pHLA
binding range56, which was consistent with our tetramer-
avidity data.
Overall, A68/NP145+CD8+ T cells have an immunodominant
memory potential, as detected in 35% of our donors. However, as
the remaining 65% of HLA-A*68:01-expressing donors had low
precursor frequency of A68/NP145+CD8+ T cells, which indicates
possible difﬁculties with the recruitment of A68/NP145+CD8+
TCRαβ clonotypes during inﬂuenza-speciﬁc responses, as com-
pared with the engagement of TCRαβ clones against universal
inﬂuenza CD8+ T cell epitopes in the same donors. A potential
low CD8+ T cell frequency against this one NP145/HLA-A*68:01
epitope may not greatly affect the disease severity in individuals
with additional HLAs capable of presenting universal inﬂuenza
epitopes mounting robust inﬂuenza CD8+ T cell responses
against these universal epitopes. However, as the frequency of the
HLA-A*68:01 allomorph is especially high among the Indigenous
populations globally including Southern America (http://www.
allelefrequencies.net) and Australia57. These Indigenous popula-
tions often lack HLA allomorphs that present universal inﬂuenza
epitopes and thus might lack inﬂuenza virus-speciﬁc CD8+ T cell
responses toward other HLAs9. The fact that the A68/NP145-
speciﬁc CD8+ T cells have an immunodominance potential
makes them an interesting target to stimulate by novel CD8+ T
cell-inducing inﬂuenza vaccines. Future research is needed to
understand whether their inﬂuenza virus-speciﬁc CD8+ T cell
response will beneﬁt from repeatedly boosting, for example by
novel CD8+ T cell-inducing inﬂuenza vaccines.
Methods
Human blood samples. Our study assessed inﬂuenza-speciﬁc CD8+ T cell
responses in 18 HLA-A*68:01-expressing donors. These 18 donors represent all of
our HLA-A*68:01 individuals recruited and HLA typed across six different HLA-
typed cohorts, consisting of a total of ∼500 donors. Peripheral blood mononuclear
cells (PBMCs) were obtained from donors recruited through the University of
Melbourne (UoM), Australian Red Cross Lifeblood (ARCL) (Melbourne), Deep-
dene Medical Clinic (DMC) (Melbourne), Menzies School of Health Research,
Royal Melbourne Hospital (RMH) and the Alfred Hospital (AH) (Table 1). Ficoll-
Paque (GE Health-care, Uppsala, Sweden) gradient centrifugation was used to
isolate PBMCs, which were subsequently cryopreserved in liquid N2 until required.
A68/NP145+CD8+ T cell responses for donors 1, 2, and 3 were accessed at two
separate time-points, in 2015 and 2018 (Table 1). HLA class I and class II mole-
cular genotyping was performed from genomic DNA by the ARCL. Human
experimental work was conducted according to the Declaration of Helsinki prin-
ciples and approved by the Human Research Ethics Committee (HREC) of the
University of Melbourne (Ethics ID #1443389.4), Northern Territory Department
of Health and Menzies School of Health Research (ID #HREC-2012-1928) for LIFT
donors57 and HREC of Monash Health and Melbourne Health (ID #HREC/15/
MonH/64) for RMH donors and Alfred Hospital (ID #280/14) for AH donors. All
donors provided informed written consent.
The vaccination and infection history of the donors were predominantly
unknown. However, it is important to note that the current inactivated inﬂuenza
vaccine does not induce inﬂuenza-speciﬁc CD8+ T cells responses4, thus recentT
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inﬂuenza immunisation would not affect CD8+ T cell responses tested in
this study.
Protein expression, puriﬁcation, and crystallization. Soluble class I hetero-
dimers of HLA-A*68:01-containing NP145 peptide were prepared by expressing the
heavy chain and the β2-microglobulin proteins separately as inclusion body in a
BL21 E. Coli strain. After several washes, the inclusion bodies were solubilized in
6M guanidine before being use for refold. The refolding buffer contained 0.1 M
Tris-HCl pH8, 2 mM EDTA, 400 mM L-Arginine-HCl, 0.5 and 5 mM Glutathione
oxidized and reduced, respectively. Into the chilled refolding buffer was added
90 mg of heavy chain inclusion bodies; 20 mg of β2 m inclusion bodies, and 10 mg
of the NP145 peptide (purchased from GLbiochem) dissolved in 400 μL of DMSO.
After 3 days, the protein was dialyzed and puriﬁed using anion exchange and size
exclusion columns. Crystals of the HLA-A*68:01-NP145 grew at 2.5 mg/ml in
8–14% v/w PEG3350, 0.1 M NaCl, 0.1 M Hepes pH 7.4, 20 mM MgCl2, and 5 mM
CdCl2. The crystals were soaked into a cryoprotectant solution containing the
mother liquor solution enriched at 25% v/w PEG3350, and ﬂash frozen in liquid
nitrogen. Data were collected on the MX2 beamline58 at the Australian Synchro-
tron, Clayton using an ADSC 315r CCD detector (at 100 K). Diffraction data were
processed using XDS software59, and scaled with SCALA software60 from the
CCP4 suite61. The structure of HLA-A*68:01-NP145 complex was solved by
molecular replacement using PHASER (S0907444901012471) with the previously
solved structure of HLA-A*68:01 as model (PDB accession number 4HWZ62)
without the bound peptide. The model was reﬁned with Buster software63 after
multiple manual model building run to ﬁt the NP145 peptide in the structure using
Coot software64. The ﬁnal model has been validated using the Protein Data Base
validation website, ﬁnal reﬁnement statistics are summarized in Supplementary
Table 1. All molecular graphics representations were created using MacPyMOL
v1.7.6.365.
Viral sequence analysis. To assess the frequency of amino acid variations in the
NP145 peptide in human A/H1N1 (1918–1957, 1977−2009, and 2009–2018), A/
H2N2 (1957–1968), A/H3N2 (1968–2018), H5N1 (1997–2014) and H7N9
(2013–2017) viruses, all full-length NP amino acid sequences available in the
inﬂuenza virus resource database of the National Center for Biotechnology Infor-
mation (NCBI; http://www.ncbi.nlm.nih.gov/genomes/FLU), as of 31 July 2018,
were downloaded. Sequences with large deletions were excluded using BioEdit, the
remaining dataset was analyzed in Ugene 1.16.1 (http://ugene.unipro.ru; Unipro,
Novosibirsk, Russia) to assess the frequency of variations at different positions in
the NP145 peptide. Viruses were analyzed in Excel to determine whether observed
frequencies were the result of cluster formation and whether certain mutations
became ﬁxed in time.
Peptides and tetramers. Variants of the IAV NP145 peptide (DATYQRTRALVR,
DTTYQRTRALVR, and DVTYQRTRALVR) were purchased from GenScript
(Piscataway, NJ, USA). HLA−A*68:01-NP145 (DATYQRTRALVR) monomers
were generated in house by refolding each peptide with its restricted HLA α-heavy
chain-BirA and β2-microglobulin66 before 8:1 conjugation with PE-streptavidin or
APC-streptavidin (BD Biosciences, San Jose, CA, USA) to form tetramers.
Generation of T cell lines. To amplify inﬂuenza virus-speciﬁc CD8+ T cells
directed at the HLA-A*68:01-restricted NP145 epitope, autologous PBMCs (~3 ×
106 cells) from HLA-A*68:01 donors were pulsed with 10 μM NP145 peptide
(DATYQRTRALVR, DTTYQRTRALVR or pool of DATYQRTRALVR,
DTTYQRTRALVR, and DVTYQRTRALVR) in 1 ml serum-free RPMI1640 med-
ium (Invitrogen) for 90 min at 37°C and washed with RPMI. Peptide-pulsed
PBMCs were then incubated with autologous nonpeptide-pulsed PBMCs (6 × 106
cells) and cultured for 10 days in cRPMI (RPMI supplemented with 2 mM L-
glutamine (Gibco), 1 mM MEM sodium pyruvate (Gibco), 100 µM MEM non-
essential amino acids (Gibco), 5 mM HEPES buffer solution Gibco), 55 µM 2-
mercaptoethanol (Gibco), 100 U/ml penicillin (Gibco), 100 µg/ml streptomycin
(Gibco), and 10% fetal bovine serum (Gibco)). Cultures were supplemented on day
4 with 20 U/ml rIL2 (Roche, Basel, Switzerland) and then every 3–4 days with fresh
media36.
Intracellular staining. Expanded A68/NP145+ CD8+ T cells were stimulated with
1 µM peptide (DATYQRTRALVR, DTTYQRTRALVR, DVTYQRTRALVR or pool
of DATYQRTRALVR, DTTYQRTRALVR, and DVTYQRTRALVR) and cultured
for 5 h in the presence of 10 U/ml rIL2 and Golgi Stop (BD Biosciences). Following
activation, cells were surface stained for 30 min with human anti-CD3-BV510
(1:200, Biolegend #317332), anti-CD4-BV650 (1:200, BD Horizon #563875), anti-
CD14-APC-H7 (1:100, BD Pharmingen #560180), anti-CD19-APC-H7 (1:100, BD
Pharmingen #560177), anti-CD8-PerCPCy5.5 (1:100, BD Pharmingen #565310),
Live/Dead near-infrared (1:800, Invitrogen), and PE-streptavidin-conjugated A68/
NP145 (DATYQRTRALVR) tetramer. Cells were ﬁxed with BD Fix-Perm buffer
(BD Biosciences) for 20 min, before intracellular staining for 30 min with human
anti-IFN-γ-V450 (1:100, BD Horizon #560371) in perm wash buffer (BD Bios-
ciences). Cells were washed, acquired on the BD Fortessa (BD Biosciences) and
analyzed using the Flowjo software (Treestar, OR, USA).
Magnetic enrichment of NP145+CD8+ T cells ex vivo. PBMCs or T cell lines
(1–5 × 107) were thawed in cRPMI medium supplemented with 50 U/ml Benzo-
nase (Novagen Merck). Cells were washed once in magnetic-activated cell sorting
(MACS) buffer (PBS supplemented with 0.5% Bovine Serum Albumin (BSA)
(Sigma) and 2 mM EDTA) and incubated with anti-human FcR block [20 µl/1 ×
107 cells] (Milteny Biotec) for 15 min on ice and subsequently stained with PE-
and/or APC-streptavidin-conjugated tetramers [1:100 in MACS buffer] for 1 h at
room temperature. After one wash, cells were incubated for 30 min on ice with
100 µl anti-PE and/or 100 µl anti-APC MicroBeads (Milteny Biotec) in 400 or
300 µl MACS buffer, respectively. Cells were washed twice before passing through a
LS column (Milteny Biotec) to enrich for tetramer-positive cells45,67. Cells were
then surfaced stained in MACS buffer using human anti-CD45RA-FITC (1:200,
BD Biosciences #555488), anti-CD8-PerCP-Cy5.5 (1:200, BD Biosciences
#565310), anti-CD27−APC (1:50, BD Biosciences #337169), or anti-CD27-BV711
(1:200, BD Horizon #563167), anti-CD3-AF700 (1:50, BD Biosciences #557943),
anti-CD14-APC-Cy7 (1:100, BD Biosciences #560180), anti-CD19 (1:100, BD
Biosciences #560177), anti-CD62L-V450 (1:100, eBioscience #48-0629-42), anti-
CD4-BV650 (1:100), anti-CD56-BV785 (1:100, BD Horizon #564058), anti-CD95-
PECF594 (1:100, BD Horizon #562395), anti-CCR7-PeCy7 (1:50, BD Biosciences
#557648), and Live/Dead ﬁxable aqua dead-cell stain (1:800, Invitrogen) for 30 min
on ice. Cells were subsequently washed once and ﬁxed with 1% paraformaldehyde
(ProSciTec) for acquiring on a LSRFortesa II (BD Biosciences) or resuspended in
MACS buffer for single cell-(index)-sorting using a BD FACSAria III (BD Bios-
ciences), followed by the analysis using a FlowJo software (BD Biosciences).
Single-cell RT-PCR and TCR sequencing. A68/NP145 enriched cells were indi-
vidually (index-) sorted into chilled 96-well twin.tec PCR plates (Eppendorf,
Hamburg, Germany) and immediately stored at −80 °C until required. Single-cell
paired CDR3α and CDR3β regions were analyzed by multiplex nested RT-PCR and
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followed by sequencing of the CDRα and CDRβ products43,47,68. Brieﬂy, cDNA
was synthesized from single cells in PCR plates in 2.5 µl reaction mixes, each
containing 0.5 µl 5× VILO reaction mix (Invitrogen), 0.25 µl 10× SuperScript
enzyme mix (Invitrogen), and 0.1% Triton X-100 (Sigma), which were incubated at
25°C for 10 min, 42°C for 120 min, and 85 °C for 5 min. TCR transcripts from each
cell were ampliﬁed by multiplex nested PCR in 25 µl reaction mixes containing
2.5 µl cDNA. First-round PCR was performed with 2.5 µl 10× PCR buffer (con-
taining 15 mM MgCL2) (Qiagen), 0.5 µl of 10 mM dNTP (Invitrogen), 0.15 µl Taq
DNA polymerase (5 units/µl) (Qiagen), 2.5 pmol each of the external sense TRAV
and TRBV and external antisense TRAC and TRBC primers (Supplementary
Table 4). A total of 2.5 µl aliquots of the ﬁrst-round PCR products served as
templates for two separate second-round PCRs that incorporated, respectively, an
internal sense TRAV and internal sense TRAC primers (Supplementary Table 4) or
internal sense TRBV and internal antisense TRBC primers (Supplementary
Table 4). The second-round PCR used CoralLoad PCR buffer 10× (Qiagen) instead
of 10× PCR buffer. PCR conditions for external and internal PCR round were 95 °C
for 2 min, followed by 35 cycles of 95 °C for 20 s, 52°C for 20 s, and 72°C for 45 s,
followed by one step of 72°C for 7 min. PCR products were puriﬁed and sequenced
with the respective internal TRAC and TRBC primer (Supplementary Table 4).
Sequences were analyzed with FlinchTV. V–J regions were identiﬁed by IMGT
query (www.imgt.org/IMGT_vquest). TCR sequences were parsed using the
TCRdist analytical pipeline69. Clonotypes were deﬁned as single-cell TCRαβ pairs
that exhibit the same V, J, and CDR3 regions. Circos plots were generated using the
online Circos software package (http://mkweb.bcgsc.ca)70.
Statistical analysis. The data were analyzed by SPSS statistics 25 using a
Mann–Withney test and differences were considered signiﬁcant at a p value of
<0.05. Medium and high responder groups were pooled to ensure adequate power
for statistical analysis.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
PDB accession number for the HLA−A*68:01-NP145 complex structure is 6PBH. TCR
sequence data have been deposited into VDJdb [https://vdjdb.cdr3.net]. The source data
underlying Figs. 2–8, Supplementary Figs. 2–4, Table 2 and Supplementary Table 3 are
provided as a Source Data ﬁle. All other data are available from the authors upon request.
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